Edward Van Wezel | partner
Bgv Biogeneration Ventures

Edward Van Wezel, partner, Bgv Biogeneration Ventures

Edward currently serves on the supervisory boards of Progentix Orthobiology, Cristal Therapeutics, Synaffix, Staten Biotechnology, Escalier BioSciences and Scenic Biotech. He served on the supervisory boards of BioCeros (sold in 2011), Noviogendix (acquired by MDxHealth) and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca). Edward is also on the board of Mibiton.
Edward started his career as process engineer for Chiron Inc.. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands.

Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.


Conference Day 1 - Tuesday 31st March 2020 @ 14:20

Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

  • Compare and contrast different VC methodologies
  • What other types of innovative funding is there?
  • Unorthodox ways to get money
  • What do pharma look for when in-licensing?
last published: 04/Jun/20 08:25 GMT

back to speakers